Aethlon Medical Receives Ethics Board Approval To Add Second Site To Its Ongoing Clinical Trial Of Its Hemopurifier To Treat Severe COVID-19 In India
Aethlon Medical Receives Ethics Board Approval To Add Second Site To Its Ongoing Clinical Trial Of Its Hemopurifier To Treat Severe COVID-19 In India
Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced that it has received Ethics Review Board (ERB) approval from the Maulana Azad Medical College (MAMC), for a second site for its ongoing clinical trial of Aethlon's Hemopurifier to treat severe COVID-19 in India.
MAMC was established in 1958 and is located in New Delhi, India. MAMC is affiliated with the University of Delhi and is operated by the Delhi government.
"Cases of COVID-19 infection that require hospitalization continue to occur in India. The addition of MAMC as a second high quality clinical site may improve our enrollment of patients who go on to require ICU care for severe infection," commented Steven LaRosa, M.D., Chief Medical Officer of Aethlon Medical.
Aethlon Medical's clinical trial of the Hemopurifier in patients with SARS-CoV-2, or COVID-19, in the ICU with severe or life-threatening disease, is designed to enroll up to 15 patients at up to three centers throughout India. The initial site for the ongoing trial is Medanta Medicity Hospital in Gurgaon, India, and currently remains open for enrollment, with one patient treated to date.
Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, today announced that it has received Ethics Review Board (ERB) approval from the Maulana Azad Medical College (MAMC), for a second site for its ongoing clinical trial of Aethlon's Hemopurifier to treat severe COVID-19 in India.
专注于开发诊断和治疗癌症和危及生命的传染病产品的医疗治疗公司Aethlon Medical, Inc.（纳斯达克股票代码：AEMD）今天宣布，它已获得毛拉纳·阿扎德医学院（MAMC）的伦理审查委员会（ERB）的批准，这是其正在印度治疗严重 COVID-19 的临床试验的第二个地点。
MAMC was established in 1958 and is located in New Delhi, India. MAMC is affiliated with the University of Delhi and is operated by the Delhi government.
MAMC 成立于 1958 年，位于印度新德里。MAMC 隶属于德里大学，由德里政府运营。
"Cases of COVID-19 infection that require hospitalization continue to occur in India. The addition of MAMC as a second high quality clinical site may improve our enrollment of patients who go on to require ICU care for severe infection," commented Steven LaRosa, M.D., Chief Medical Officer of Aethlon Medical.
“需要住院的 COVID-19 感染病例继续在印度发生。Aethlon Medical首席医学官Steven LaRosa医学博士评论说，增加MAMC作为第二个高质量临床中心可能会提高我们对因严重感染而需要重症监护的患者的入组人数。
Aethlon Medical's clinical trial of the Hemopurifier in patients with SARS-CoV-2, or COVID-19, in the ICU with severe or life-threatening disease, is designed to enroll up to 15 patients at up to three centers throughout India. The initial site for the ongoing trial is Medanta Medicity Hospital in Gurgaon, India, and currently remains open for enrollment, with one patient treated to date.
Aethlon Medical在重症监护病房对患有严重或危及生命的疾病的SARS-CoV-2或 COVID-19 患者进行的血清净化器临床试验旨在在印度最多三个中心招收多达15名患者。正在进行的试验的初始地点是印度古尔冈的Medanta Medicity医院，目前仍在接受入组，迄今为止已治疗了一名患者。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧